Up 28% since October, why are CSL shares attracting regulator scrutiny?

CSL shares have soared 28% since the end of October.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are in the red today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed on Friday trading for $299.79. In morning trade on Monday, shares are swapping hands for $296.90, down 1%.

For some context, the ASX 200 is also down 1% at this same time.

Despite that dip, that still sees the stock up 28% since 30 October.

And it makes CSL the third largest company listed on the ASX, with a market cap just shy of $145 billion.

But it's not the big surge in CSL shares that's brought the biotechnology giant under regulatory scrutiny in the United Kingdom. Or, at least, not directly.

What's happening with CSL shares in the UK?

As you may be aware, CSL's three operating segments are CSL Behring, CSL Vifor, and its Seqirus businesses.

CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies. The company acquired Vifor Pharma for US$11.7 billion in 2022 in a deal that boosted CSL shares once completed.

At its capital markets day presentation in October management noted, "CSL Vifor will continue to grow its leading iron franchise through market expansion and life cycle management."

CSL's iron-deficiency treatment is known as Ferinject.

But in possible headwinds for CSL shares, Vifor has run into a potentially sticky patch in the UK, where some four million people suffer from iron deficiency anaemia.

As Reuters reports, the UK's Competition and Markets Authority (CMA) launched an investigation last Wednesday into whether Vifor Pharma disparaged a competing iron-deficiency treatment produced by its competitor Pharmacosmos to benefit Ferinject.

CMA will investigate whether the company impinged on Pharmacosmo's business by making misleading claims to medical professionals about the safety and efficacy of Monofer, Pharmacosmos's competing treatment.

CSL has not yet responded to the allegations.

But if the CMA finds the company did engage in anti-competitive practices, CSL shares could come under pressure amid a potentially sizeable fine and the accompanying reputational damage.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »